New drug combo targets Hard-to-Treat cancers
NCT ID NCT04866134
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two experimental drugs, ERAS-007 and ERAS-601, in people with advanced solid tumors that have not responded to standard treatments. The drugs are taken orally and aim to block signals that help cancer grow. The trial will first find safe doses and then check if the drugs can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ERAS-007 (ERK inhibitor) and ERAS-601 (SHP2 inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so the drugs may not prove effective or may have significant side effects. The results may not apply to all tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute (Florida Cancer Specialists)
Sarasota, Florida, 34232, United States
-
Sarah Cannon Research Institute (HealthONE)
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute (Tennessee Oncology)
Nashville, Tennessee, 37203, United States